The story · written by gpt-6,
Sierra Leone’s Pharmacy Board set out a licensed route for growing and processing medical cannabis in guidelines effective from 17 May 2024.[1] The document focused on production for export, with requirements for applicants, planting material, secure premises and consistent product quality.[1]
An older permission power gained practical rules
The legal basis came from the 2001 pharmacy law, which required the Board’s written consent to cultivate plants yielding narcotic drugs.[2] The guidelines expressly relied on that power for cannabis cultivation and the production of cannabis and extracts for medical and scientific purposes.[1]
The same pharmacy law contained severe cannabis offences, including a minimum fifteen-year sentence for an individual convicted under it.[2] Permission for licensed production therefore operated alongside criminal restrictions on unauthorised cannabis activity.[1][2]
Applicants needed more than a field
Applications could come from licensed companies, registered manufacturers, and approved government or nongovernmental organisations running health programmes.[1] They had to submit business and tax documents, an application form and a fee to the Board.[1]
The guidelines required applicants and relevant business associates to be suitable people to hold a licence.[1] Staff suitability mattered too: the Board treated employees as a possible route for cannabis to leave the authorised supply chain.[1]
Security policies had to deter entry, detect breaches and set out a response.[1] Failure to meet the security requirements could lead to a licence being revoked.[1]
The crop had to be traceable
Seeds and other planting material had to carry information identifying their species, variety, chemical type and origin.[1] The rules called for traceable material and female cuttings for production, with monitoring for male plants and unwanted varieties.[1]
The quality requirements followed the crop through cultivation, harvesting, drying and packaging.[1] Manufacturers had to follow good agricultural, laboratory and manufacturing practices, while the Board’s inspectorate and enforcement staff checked licensed sites and applicants.[1]
Export production shaped the route
The guidelines described cannabis as a starting material for pharmaceutical products and identified export production as their purpose.[1] Their emphasis was on reliable quality, patient safety and preventing diversion from licensed operations.[1]
For Sierra Leone, this placed a documented medical production route within a wider system of criminal drug controls.[1][2] The practical work for applicants was to secure permission and satisfy the Board’s requirements at each stage from planting material to processed product.[1]
Listed for context. No score change is recorded for Sierra Leone here.
References
- Guideline for the Cultivation and Processing of Medical Cannabis, PBSL/GL/022, Version 02Pharmacy Board of Sierra Leone · 2024 · Issue date 15 May 2024; effective 17 May 2024; pp. 4–8, 12–13 and 22–25archived
- The Pharmacy and Drugs Act, 2001, No. 12Government of Sierra Leone · 2001 · Commencement 13 December 2001; §§ 29, 48–50, 59(3), 65–66; printed pp. 26–27, 30–31 and 34archived
Checked. The date and the event were compared with a source that was read.